Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?

Last updated: December 20, 2024
Sponsor: University of California, San Diego
Overall Status: Active - Recruiting

Phase

1

Condition

Sleep Disorders

Sleep Apnea Syndromes

Treatment

Room Air

Continuous Positive Airway Pressure Machine

Supplemental Oxygen

Clinical Study ID

NCT05094271
200228
  • Ages 65-85
  • All Genders

Study Summary

Obstructive sleep apnea (OSA) is common in older adults and has recently been implicated in pathogenesis of Alzheimer's disease (AD). Research has shown that sleep disruptions have caused memory impairment. Sleep apnea is a form of sleep disruption. We would like to examine how obstructive sleep apnea may contribute to the progression of Alzheimer's disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age 65-85 years

  2. Gender: Men or Women

  3. MOCA > 26

  4. Independently living and able to drive

  5. OSA (AHI ≥ 15/h) or no OSA

  6. Subjects must consent to waiving their right to obtain their PHS score (since thescore is not yet actionable and could lead to social stress and ethical dilemmas)

Exclusion

Exclusion Criteria:

  1. Currently smoking

  2. History of COPD or asthma

  3. Heart Failure Class III or IV, unstable cardiovascular disease, or uncontrolledhypertension

  4. Neuromuscular Disease

  5. Drowsy Driving (ESS > 18/24)

  6. Inability to complete study procedures, such as questionnaire that are onlyavailable/validated in English

  7. Lack of decisional capacity to provide informed consent

  8. Participants in whom magnetic resonance imaging Magnetic Resonance Imaging [MRI] iscontraindicated including, but not limited to, those with a pacemaker, presence ofmetallic fragments near the eyes or spinal cord, or cochlear implant

  9. Presence of a brain tumor or lobar stroke

  10. Current drug or alcohol abuse/dependence

  11. Prisoners

Study Design

Total Participants: 260
Treatment Group(s): 3
Primary Treatment: Room Air
Phase: 1
Study Start date:
June 30, 2021
Estimated Completion Date:
May 20, 2025

Study Description

Aim 1: We will assess the endotypes (mechanisms) underlying OSA in elderly individuals known to be high risk for AD (vs. non-OSA matched controls) using novel recently validated simplified techniques which do not require burdensome complex overnight experiments to assess endotypes (primary outcome loop gain). We will further assess the predicted response to O2 therapy in terms of respiratory outcomes among elderly OSA patients with varying levels of loop gain and pharyngeal collapsibility.

Hypothesis 1: A substantial proportion of high AD risk patients with OSA should be O2 responsive as predicted using pathophysiological assessments.

Aim 2: We will perform an overnight mechanistic study of oxygen therapy vs. room air in high AD risk patients with OSA (recruited from Aim 1 and others if necessary). Given the frequent intolerance of PAP in elderly patients, we anticipate that oxygen therapy may be a viable therapeutic approach in this fragile population. We will focus on respiratory outcomes (primary outcome: apnea hypopnea index) but also assess sleep dependent memory consolidation on word pairs task given the major impact in the elderly.

Hypothesis 2: O2, compared to room air, will improve OSA and neurocognitive outcomes in select elderly OSA patients at risk of AD.

Aim 3: Preclinical AD with OSA and non-OSA controls, from Aim 1 will have structural and molecular brain imaging focusing on hippocampal atrophy as a predictor of memory consolidation. We will also assess amyloid and tau in the medial temporal region as function of OSA severity and as a predictor of neurocognitive function. This aim will lay the groundwork for designing a robust clinical trial using neuroimaging outcomes.

Hypothesis 3: Impairment in memory consolidation is a function of hippocampal size in OSA patients at risk of AD.

Aim 4: We will perform a pilot randomized trial of oxygen vs. PAP therapy in OSA patients with preclinical AD.

Hypothesis 4: In preclinical AD with OSA, oxygen will be a viable therapeutic strategy to improve memory.

Connect with a study center

  • UCSD Sleep Research

    La Jolla, California 92037
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.